Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-17T21:26:16.067Z Has data issue: false hasContentIssue false
  • English
  • Français

Alpha Methyldopahydrazine as an Adjunct to Levodopa Therapy in Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

D.W. Paty ,
N. Jaatoul ,
A. Kertesz  and
W. McInnis
D.W. Paty*
Affiliation:
Department of Clinical Neurological Sciences, The University of Western Ontario
N. Jaatoul
Affiliation:
Department of Clinical Neurological Sciences, The University of Western Ontario
A. Kertesz
Affiliation:
Department of Clinical Neurological Sciences, The University of Western Ontario
W. McInnis
Affiliation:
Department of Clinical Neurological Sciences, The University of Western Ontario
*
University Hospital, 339 Windermere Rd., London, Ontario N6G 2K3
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A double-blind, double-observer study was carried out in twenty-five patients with Parkinson’s disease. Alpha methyldopahydrazine in combination with L-dopa was compared to placebo with L-dopa. Combination therapy resulted in a reduction in L-dopa dosage to 1/3 of the amount required during the baseline. There were no side effects attributed directly to the alpha methyldopahydrazine. The overall incidence of side effects in the two groups was similar but the combination therapy significantly reduced the incidence of nausea and vomiting. The limiting factor in the combination therapy was the presence of L-dopa induced dyskinesias.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 2 , Issue 3 , August 1975 , pp. 169 - 172
Copyright
Copyright © Canadian Neurological Sciences Federation 1975

References

REFERENCES

Bartholini, G., and Pletscher, A. (1968). Cerebral accumulation and metabolism of C14-dopa after selective inhibition of decarboxylase. J. Pharmacol Exp Ther 161: 14–20.Google ScholarPubMed
Chase, T.N. and Watanbe, A.M. (1972). Methyldopahydrazine as an adjunct to L-dopa therapy in Parkinsonism. Neurology 22: 384–392.CrossRefGoogle ScholarPubMed
Mars, H. (1973). Modification of Levodopa effect by systemic decarboxylase inhibition. Arch. Neurol. 28: 91–95.CrossRefGoogle ScholarPubMed
Marsden, C.D., Parkes, J.D., and Reese, J.E. (1973). A year’s comparison of treatment of patients with Parkinson’s disease with Levodopa combined with Carbidopa versus treatment with Levodopa alone. Lancet 4: 1459–1462.CrossRefGoogle Scholar
Symposium On Levodopa In Parkinson’s Disease (1972). McDowell, Fletcher Editor. Neurology 22: No. 5, Part 2. 1–102.Google Scholar